Immunome (IMNM) Cash from Investing Activities (2019 - 2026)
Immunome (IMNM) posted Cash from Investing Activities of -$12.0 million for Q1 2026, down 200.48% on a QoQ basis from -$4.0 million in Q4 2025, and down 336.12% year-over-year from $5.1 million in Q1 2025.
Immunome (IMNM) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Immunome's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$12.0 million for Q1 2026.
- Quarterly Cash from Investing Activities fell 336.12% year-over-year to -$12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.7 million (up 202.23% YoY) and the FY2025 annual result came in at $60.8 million, up 171.48% from the prior year.
- Cash from Investing Activities was -$12.0 million for Q1 2026 at Immunome, down from -$4.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $123.9 million in Q3 2025 and bottomed at -$81.7 million in Q2 2024.
- A 5-year average of -$4.2 million and a median of -$138000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 41569.44% — and 2024, when it surged 67038.89%.
- Immunome's Cash from Investing Activities stood at -$72000.0 in 2022, then tumbled by 41569.44% to -$30.0 million in 2023, then soared by 132.52% to $9.8 million in 2024, then tumbled by 140.98% to -$4.0 million in 2025, then slumped by 200.48% to -$12.0 million in 2026.
- Business Quant data shows IMNM's Cash from Investing Activities at -$12.0 million in Q1 2026, -$4.0 million in Q4 2025, and $123.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Immunome | 2.51 Bn | 1.93 Bn | - | -12.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.02 Mn |
| Mar 31, 2026 | -12.02 Mn |
| Dec 31, 2025 | -4.00 Mn |
| Dec 31, 2025 | -4.00 Mn |
| Sep 30, 2025 | 123.88 Mn |
| Sep 30, 2025 | 123.88 Mn |
| Jun 30, 2025 | -64.17 Mn |
| Jun 30, 2025 | -64.17 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Dec 31, 2024 | 9.76 Mn |
| Dec 31, 2024 | 9.76 Mn |
| Sep 30, 2024 | 24.10 Mn |
| Sep 30, 2024 | 24.10 Mn |
| Jun 30, 2024 | -81.69 Mn |
| Jun 30, 2024 | -81.69 Mn |
| Mar 31, 2024 | -37.23 Mn |
| Mar 31, 2024 | -37.23 Mn |
| Dec 31, 2023 | -30.00 Mn |
| Dec 31, 2023 | -30.00 Mn |